126 related articles for article (PubMed ID: 17293494)
1. Antithrombotic activity of kininogen is mediated by inhibitory effects of domain 3 during arterial injury in vivo.
Hassan S; Sainz IM; Khan MM; Bradford HN; Isordia-Salas I; Kashem SW; Sartor RB; Colman RW
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2959-65. PubMed ID: 17293494
[TBL] [Abstract][Full Text] [Related]
2. Cleaved high-molecular-weight kininogen inhibits neointima formation following vascular injury.
Daniel JM; Reich F; Dutzmann J; Weisheit S; Teske R; Gündüz D; Bauersachs J; Preissner KT; Sedding DG
Thromb Haemost; 2015 Aug; 114(3):603-13. PubMed ID: 26063414
[TBL] [Abstract][Full Text] [Related]
3. Potential pharmacological applications of the antithrombotic molecule high molecular weight kininogen.
Chavakis T; Preissner KT
Curr Vasc Pharmacol; 2003 Mar; 1(1):59-64. PubMed ID: 15320853
[TBL] [Abstract][Full Text] [Related]
4. High-molecular-weight kininogen fragments stimulate the secretion of cytokines and chemokines through uPAR, Mac-1, and gC1qR in monocytes.
Khan MM; Bradford HN; Isordia-Salas I; Liu Y; Wu Y; Espinola RG; Ghebrehiwet B; Colman RW
Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2260-6. PubMed ID: 16902163
[TBL] [Abstract][Full Text] [Related]
5. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis.
Colman RW; Jameson BA; Lin Y; Johnson D; Mousa SA
Blood; 2000 Jan; 95(2):543-50. PubMed ID: 10627460
[TBL] [Abstract][Full Text] [Related]
6. Thrombin interaction with a recombinant N-terminal extracellular domain of the thrombin receptor in an acellular system.
Bouton MC; Jandrot-Perrus M; Moog S; Cazenave JP; Guillin MC; Lanza F
Biochem J; 1995 Jan; 305 ( Pt 2)(Pt 2):635-41. PubMed ID: 7832783
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin.
Kelly AB; Maraganore JM; Bourdon P; Hanson SR; Harker LA
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):6040-4. PubMed ID: 1385867
[TBL] [Abstract][Full Text] [Related]
8. Kininogens are antithrombotic proteins In vivo.
Colman RW; White JV; Scovell S; Stadnicki A; Sartor RB
Arterioscler Thromb Vasc Biol; 1999 Sep; 19(9):2245-50. PubMed ID: 10479669
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of platelet adhesion and aggregation by a defined region (Gly-486-Lys-502) of high molecular weight kininogen.
Chavakis T; Boeckel N; Santoso S; Voss R; Isordia-Salas I; Pixley RA; Morgenstern E; Colman RW; Preissner KT
J Biol Chem; 2002 Jun; 277(26):23157-64. PubMed ID: 11970955
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of angiogenesis by cleaved high molecular weight kininogen (HKa) and HKa domain 5.
McCrae KR; Doñate F; Merkulov S; Sun D; Qi X; Shaw DE
Curr Cancer Drug Targets; 2005 Nov; 5(7):519-28. PubMed ID: 16305348
[TBL] [Abstract][Full Text] [Related]
11. Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5.
Zhang JC; Claffey K; Sakthivel R; Darzynkiewicz Z; Shaw DE; Leal J; Wang YC; Lu FM; McCrae KR
FASEB J; 2000 Dec; 14(15):2589-600. PubMed ID: 11099478
[TBL] [Abstract][Full Text] [Related]
12. Thrombin-induced platelet aggregation is inhibited by the heptapeptide Leu271-Ala277 of domain 3 in the heavy chain of high molecular weight kininogen.
Kunapuli SP; Bradford HN; Jameson BA; DeLa Cadena RA; Rick L; Wassell RP; Colman RW
J Biol Chem; 1996 May; 271(19):11228-35. PubMed ID: 8626672
[TBL] [Abstract][Full Text] [Related]
13. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L
Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972
[TBL] [Abstract][Full Text] [Related]
14. Kininostatin as an antiangiogenic inhibitor: what we know and what we do not know.
Guo YL; Wang S; Colman RW
Int Immunopharmacol; 2002 Dec; 2(13-14):1931-40. PubMed ID: 12489806
[TBL] [Abstract][Full Text] [Related]
15. The inhibition of tube formation in a collagen-fibrinogen, three-dimensional gel by cleaved kininogen (HKa) and HK domain 5 (D5) is dependent on Src family kinases.
Liu Y; Sainz IM; Wu Y; Pixley R; Espinola RG; Hassan S; Khan MM; Colman RW
Exp Cell Res; 2008 Feb; 314(4):774-88. PubMed ID: 18062965
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of angiogenesis by two-chain high molecular weight kininogen (HKa) and kininogen-derived polypeptides.
Zhang JC; Qi X; Juarez J; Plunkett M; Donaté F; Sakthivel R; Mazar AP; McCrae KR
Can J Physiol Pharmacol; 2002 Feb; 80(2):85-90. PubMed ID: 11934260
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic properties of water-soluble carbon monoxide-releasing molecules.
Kramkowski K; Leszczynska A; Mogielnicki A; Chlopicki S; Fedorowicz A; Grochal E; Mann B; Brzoska T; Urano T; Motterlini R; Buczko W
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2149-57. PubMed ID: 22772756
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of contact activation by a kininogen peptide (HKH20) derived from domain 5.
Nakazawa Y; Joseph K; Kaplan AP
Int Immunopharmacol; 2002 Dec; 2(13-14):1875-85. PubMed ID: 12494915
[TBL] [Abstract][Full Text] [Related]
19. The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin.
Zhang JC; Donate F; Qi X; Ziats NP; Juarez JC; Mazar AP; Pang YP; McCrae KR
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12224-9. PubMed ID: 12196635
[TBL] [Abstract][Full Text] [Related]
20. Kinetic analysis of the role of zinc in the interaction of domain 5 of high-molecular weight kininogen (HK) with heparin.
Lin Y; Pixley RA; Colman RW
Biochemistry; 2000 May; 39(17):5104-10. PubMed ID: 10819977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
